相关实验视频
Updated: May 29, 2025

07:06
Binocular Dynamic Visual Acuity in Eyeglass-Corrected Myopic Patients
Published on: March 29, 2022
2.5K
用Atropine 0.05%和Myopi-X®眼镜进行组合治疗:它是否有效控制近视?
Nilay Akagün1, Uğur Emrah Altıparmak1
1Acıbadem Ankara Hospital, Clinic of Ophthalmology, Ankara, Türkiye
Turkish journal of ophthalmology
|February 5, 2025
概括
结合Myopi-X外围渐进性添加透镜 (PAL) 与0.05%的阿特罗平,并没有显示减缓近视进展的附加效应. 这项研究发现,与单一治疗相比,折射误差或轴长变化没有显著差异. 建议进行进一步的研究.
科学领域:
- 眼科医生 眼科 眼科
- 视光学测量 视光学测量 视光学测量
- 控制近视 控制近视
背景情况:
- 近视是一种日益严重的公共卫生问题,特别是在儿童中.
- 周围渐进的添加镜头 (PAL) 和低剂量氨酸是已知的近视控制策略.
- 研究组合治疗的目的是提高近视管理的有效性.
研究的目的:
- 为了评估结合Myopi-X PALs与0.05%的氨酸用于近视控制的添加效应.
- 为了比较组合疗法的疗效与单疗法与Myopi-X PALs或单独0.05%的阿特罗宾的疗效.
主要方法:
- 对51名患者进行了回顾性横截面研究,分为三个组:Myopi-X PALs,atropine 0.05%和组合疗法.
- 记录了基线特征 (年龄,球体等价值 (SE),轴长 (AL)).
- 在治疗开始12个月后评估SE和AL的变化.
主要成果:
- 基线特征在各组之间有显著差异.
- 经过12个月 (p=0.35),两组之间没有观察到SE变化的统计学上显著差异.
- 轴长变化在各组之间也没有显著差异 (p=0.10),尽管年龄影响了AL变化 (p=0.01).
结论:
- 在这个队列中,Myopi-X PALs和0.05%的氨酸的联合治疗没有显示出对近视控制的附加益处.
- 单独的疗法显示出有效性,但它们的组合并没有在SE进展或轴延伸方面产生优异的结果.
- 需要进行更大规模的随机对照试验来验证这些发现并探索长期结果.
相关概念视频
Open Angle Glaucoma: Treatment
387
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
387
Angle Closure Glaucoma: Treatment
432
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
432
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
610
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
610
Direct-Acting Cholinergic Agonists: Therapeutic Uses
674
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
674
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Cholinergic Antagonists: Therapeutic Uses
704
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
704

